Leaders in Cancer Research & Immunotherapy

Focused on Addressing Critical

Unmet Needs

Diakonos Oncology, a clinical-stage biotechnology entity, was founded to address the critical and unmet medical need of late-stage and aggressive cancers . With a FDA Fast Track designation and unprecedented results in cancers such as Glioblastoma Multiforme (GBM), Diakonos moves closer each day to changing patient outcomes for these difficult indications.

Based on research conducted at Baylor College of Medicine, Diakonos has been privileged to work with other leading cancer institutions such as MD Anderson and UTHealth Houston.

Diakonos Oncology